经皮超声引导下肝活检的并发症:一项纳入51项队列研究超过12000例患者的系统评价与Meta分析
该研究检索多个数据库至2018年10月11日,纳入51项队列研究共12481例患者,评估经皮超声引导下肝活检的并发症率。汇总结果显示主要和次要并发症率均低(0;95%CI 0-0),出血、疼痛、气胸、血管迷走反应及死亡的特异性并发症率均为0(0-0)。作者认为经皮超声引导下肝活检可以安全实施。
要点
- 经皮超声引导下肝活检的主要和次要并发症汇总率均低(0;95%CI 0-0)。
- 出血、疼痛、气胸、血管迷走反应及死亡的特异性并发症率均为0(0-0)。
- 不同穿刺针规格及活检方式下主要并发症率均低,但部分次要并发症率因针规不同而有差异。
诊断标准与关键数值
- 汇总主要并发症率为0(95%CI 0-0),汇总次要并发症率为0(95%CI 0-0)。
- 细针抽吸的主要并发症率为0(0-0),空芯针活检的主要并发症率为0(0-0)。
- 14G针主要并发症率为0.016(0-0.032),15G为0.010(0.003-0.017),20G为0.002(-0.001-0.005),16G、17G、18G、21G和22G均为0(0-0)。
- 细针抽吸的次要并发症率为0(0-0),空芯针活检为0.001(0-0.002);15G为0.164(0.137-0.191),16G为0.316(0.113-0.519),14G、17G、18G、20G、21G和22G均为0(0-0)。
- 出血、疼痛、气胸、血管迷走反应和死亡的并发症率均为0(0-0)。
临床应用与阅片要点
- 原文结论提示经皮超声引导下肝活检可以安全实施,未给出具体阅片或操作建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Percutaneous liver biopsy (LB) has been considered the reference standard in distinguishing the degree of liver disease, but there has been no definitive systematic review to assess complication rates or potential risk factors for them.
METHODS: In this study, we searched the PubMed, Embase, Web of Science, and Scopus databases for studies appraising complication rates after percutaneous ultrasound (US)-guided LB published until October 11, 2018. The safety and efficacy of US-guided LB were estimated according to major and minor complications. Subgroups including the biopsy style, needle styles, mean number of needle insertions, study period, and specific complication items were analyzed.
RESULTS: Among 12,481 patients from 51 studies, pooled results showed a low rate (0; 95% confidence interval, 0-0) of major and minor complications. The subgroup analysis indicated that US-guided LB had a low major complication rate of 0 (0-0) for both fine-needle aspiration and core biopsy, with rates of 0.016 (0-0.032) for 14-gauge, 0.010 (0.003-0.017) for 15-gauge, 0.002 (-0.001-0.005) for 20-gauge, and 0 (0-0) for 16-, 17-, 18-, 21-, and 22-gauge needles, and low minor complication rates of 0 (0-0) for fine-needle aspiration and 0.001 (0-0.002) for core biopsy, with rates of 0.164 (0.137-0.191) for 15-gauge, 0.316 (0.113-0.519) for 16-gauge, and 0 (0-0) for 14-, 17-, 18-, 20-, 21-, and 22-gauge needles. Furthermore, specific complication rates of bleeding, pain, pneumothorax, vasovagal reactions, and death were all 0 (0-0).
CONCLUSIONS: These findings suggest that it is possible to safely perform percutaneous US-guided LB.
引用
- Tian G, Kong D, Jiang T, et al. Complications After Percutaneous Ultrasound-Guided Liver Biopsy: A Systematic Review and Meta-analysis of a Population of More Than 12,000 Patients From 51 Cohort Studies. J Ultrasound Med. 2020. PMID: 31999005. doi:10.1002/jum.15229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。